Pharmaceuticals
Indian drugmakers prepare lower-cost versions of Ozempic-like drugs as competition intensifies
By Axel Miller | 23 Mar 2026
Indian pharma companies prepare affordable semaglutide alternatives as demand for diabetes and weight-loss treatments grows in India.
India sees early competition in semaglutide as drugmakers prepare lower-cost versions
By Axel Miller | 20 Mar 2026
Indian pharmaceutical companies are exploring lower-cost semaglutide options, aiming to expand access to diabetes and obesity treatments.
Zydus and Lupin partner to co-market semaglutide injections in India
By Cygnus | 17 Mar 2026
Zydus and Lupin sign a licensing deal to co-market semaglutide injections in India, introducing a reusable pen device for diabetes and weight-management therapy.
CDSCO warns pharma firms over ‘surrogate’ ads for obesity drugs
By Axel Miller | 12 Mar 2026
CDSCO warns pharma firms against indirect promotion of GLP-1 weight-loss drugs ahead of generic launches.
Sun Pharma Gets DCGI Nod for Generic Wegovy, Set for March Launch as Semaglutide Patent Nears Expiry
By Axel Miller | 23 Jan 2026
Sun Pharma has received DCGI approval for generic semaglutide for weight management and will launch Noveltreat after the semaglutide patent expires in March 2026.
Sun Pharma Weighs $10 Billion Takeover of Organon to Expand US Footprint
By Cygnus | 19 Jan 2026
Sun Pharma is evaluating a ~$10B acquisition of Organon to expand its U.S. footprint in women's health and biosimilars, according to reports.
Johnson & Johnson Cuts Drug Prices to Secure Tariff Exemptions in Trump Deal
By Cygnus | 09 Jan 2026
Johnson & Johnson agrees to cut U.S. drug prices in exchange for tariff relief from the Trump administration and plans new factories in North Carolina and Pennsylvania.
Sun Pharma Advanced Research to Cut Workforce by 40% in Cost Optimisation Push
By Axel Miller | 08 Jan 2026
SPARC slashes 40% of workforce and consolidates labs to save $10M annually. Discover how the Sezaby PRV ruling could clear the firm’s $46M debt.
The $280 Ozempic: How a Canadian Bridge to India is Slashing U.S. Weight-Loss Costs
By Axel Miller | 07 Jan 2026
U.S. patients are bypassing $1,100 retail prices with $280 India-sourced Ozempic pens via Canada. A deep dive into the 2026 semaglutide supply chain.
US slaps sanctions on 6 Indian companies over imports from Iran
By Unnikrishnan | 03 Aug 2025
The United States on Wednesday imposed sanctions on six Indian companies, including Alchemical Solutions, Global Industrial Chemicals, Jupiter Dye Chem, Ramniklal S Gosalia & Co
